LifeMD price target raised to $10 from $9 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on LifeMD (LFMD) to $10 from $9 and keeps a Buy rating on the shares. The company reported a Q4 beat and its 2026 revenue is expected to grow 13%-19%, the analyst tells investors in a research note.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
LAZARD, INC. <LAZ.N>: KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
LAZARD, INC. : KBW CUTS TARGET PRICE TO $39.00 FROM $42.00
What Stocks Will Shine When the AI Bubble Bursts? John Rogers Says Look to Smucker's
GFL ENVIRONMENTAL INC. <GFL.TO>: CIBC CUTS TARGET PRICE TO C$77 FROM C$82
GFL ENVIRONMENTAL INC. : CIBC CUTS TARGET PRICE TO C$77 FROM C$82
Gold edges higher after hitting a two-month low
Crypto prices
More
